These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Lovastatin inhibits the proliferation of human cervical cancer hela cells through the regulation of tp53 pathway by mir-92a-1-5p.
    Author: Hu N, Lin J, Gao J, Lin S, Duan S.
    Journal: Pak J Pharm Sci; 2022 Nov; 35(6):1557-1564. PubMed ID: 36789815.
    Abstract:
    To study the effects of lovastatin on the proliferation, migration, apoptosis and cell cycle of human cervical cancer cell line HeLa in vitro and to investigate the underlying molecular mechanism. The effect of lovastatin on the expression of miRNA in HeLa cells was analyzed using an Affymetrix hybridization chip. The most significantly differentially expressed miRNA and its potential target genes were identified by Ingenuity Pathway Analysis (IPA) and verified by real-time qPCR. Lovastatin could inhibit the proliferation of HeLa cells with the IC50 of 14μmol/L. The proportion of cells in G1 phase increased, while the proportion of cells in S phase and G2/M phase decreased upon treatment with lovastatin. Real-time qPCR found that the expression of miR-192-5p was significantly upregulated (p<0.001) and miR-92a-1-5p was significantly down regulated (p<0.001). Using Ingenuity IPA analysis, MDM2 and TP53 were identified as the potential target genes of miR-192-5p and miR-92a-1-5p, respectively. The expression of TP53 (p<0.01) was significantly up regulated by Lovastatin through miR-92a-1-5p. Lovastatin can inhibit HeLa cell proliferation, promote apoptosis, inhibit migration and block the cell cycle and it may play an anti-tumor effect by down regulating the expression of miR-92a-1-5p and up regulating the expression of TP53.
    [Abstract] [Full Text] [Related] [New Search]